113 filings
Page 5 of 6
8-K
3gj1x
8 Jan 18
Other Events
12:00am
8-K
afm67f4d
14 Dec 17
Matinas BioPharma Appoints Matthew A. Wikler, M.D., M.B.A., F.I.D.S.A., to Board of Directors
12:00am
8-K
176hea77jnxc47zxs1rp
26 Oct 17
Submission of Matters to a Vote of Security Holders
12:00am
8-K
89ysh
10 Aug 17
Regulation FD Disclosure
12:00am
8-K
7df2ap7z 33lmb
8 Aug 17
Matinas BioPharma Reports 2017 Second Quarter Financial Results and Reaffirms Clinical and Regulatory Strategy to Advance MAT2203 and MAT2501
12:00am
8-K
smdofmb8qlecp
26 Jun 17
Matinas BioPharma Reports Topline Data from Phase 2 Clinical Study of Orally-Administered MAT2203 for the Treatment of Vulvovaginal Candidiasis
12:00am
8-K/A
0zcc6y7kks9
26 Jun 17
Regulation FD Disclosure
12:00am
8-K
hgvi8v9l
5 Jun 17
Regulation FD Disclosure
12:00am
8-K
rxpkh idziu
28 Apr 17
Entry into a Material Definitive Agreement
12:00am
8-K
f6pq 2vt46342vu
18 Apr 17
Matinas BioPharma Appoints Dominick DiPaolo as Senior Vice President of Quality and Regulatory Compliance
12:00am
8-K
hkskt8zz
3 Apr 17
Matinas BioPharma Reports 2016 Financial Results and Provides Corporate Update
12:00am
8-K
ecuwnc4
30 Mar 17
Matinas BioPharma Appoints Eric J. Ende, M.B.A, M.D. to its Board of Directors
12:00am
8-K
ph6h0
19 Jan 17
Matinas BioPharma Successfully Completes Warrant Tender Offer– Raises $13.5 Million from Exercise of Warrants
12:00am
8-K
w83o2 ckplzajlw
21 Dec 16
Entry into a Material Definitive Agreement
12:00am
8-K
f1gvxk
13 Oct 16
Departure of Directors or Certain Officers
12:00am
8-K
h9rb uck5
6 Oct 16
Regulation FD Disclosure
12:00am
8-K
l9p0k9i7
13 Sep 16
Matinas BioPharma Completes Private Placement of $8.0 Million
12:00am
8-K
e28xu11 xns8g
1 Aug 16
Entry into a Material Definitive Agreement
12:00am
8-K
zfs3m6
9 Mar 16
Departure of Directors or Certain Officers
12:00am
8-K
dto7oh7u0l4beul4k
5 Nov 15
Submission of Matters to a Vote of Security Holders
12:00am